Odyssey is rapidly advancing programs in immunology and oncology, focusing on targets with strong validation but for which there are no marketed solutions. The current portfolio encompasses eight declared programs with two modalities: small molecule and protein therapeutics. While some targets can be addressed with conventional drug discovery paradigms, many employ more creative approaches and emerging technologies – both computational and experimental. We plan to leverage our expertise in cancer biology, immunology, translational medicine, and data science to discover high potential targets that will offer the greatest probability of clinical success in cases where there are no promising, known targets.

Targets with
strong validation
  • Achieve the optimal target product profile for patients
  • Highest quality candidates
Expanding the
druggable genome
  • Integrate computational, structural, and next generation chemistry platforms
  • Utilize novel insights and mechanisms for target modulation
Novel, high
potential targets
  • Systems biology and proteomics for pathway mining and target identification
  • Functional and clinical genomics coupled with artificial intelligence and machine learning